Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4588 Target Snapshot

Neutrophil collagenase · SINGLE PROTEIN · Homo sapiens

1,770Compounds
230Assays
3Approved Drugs
1,758.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Neutrophil collagenase shows approved-linked disease relevance led by acne. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P22894. Start with acne, then reuse UniProt P22894 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with acne, then reuse UniProt P22894 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 2 linked drugs
Open source guide
Disease program
acne

Neutrophil collagenase shows approved-linked disease relevance led by acne. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.

Start review with acne because it currently carries approved-linked support. Linked drugs include DOXYCYCLINE, DOXYCYCLINE HYCLATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 2 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Neutrophil collagenase as ChEMBL target CHEMBL4588, mapped to UniProt P22894. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Neutrophil collagenase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4588
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P22894
Neutrophil collagenase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Neutrophil collagenase is the right protein anchor across sources, using UniProt P22894 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why acne is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelNeutrophil collagenase
UniProt AccessionP22894
Component TypeProtein
Sequence Length467 aa

Neutrophil collagenase

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Neutrophil collagenase, mapped to UniProt P22894. Sequence length is 467 aa.

Mapped IDP22894
Review nameNeutrophil collagenase
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Neutrophil collagenase shows approved-linked disease relevance led by acne. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
acne
2 linked drugs · 2 direct · 2 efficacy
Linked drugDOXYCYCLINE
Linked drugDOXYCYCLINE HYCLATE
Approved-linked Approved
malaria
2 linked drugs · 2 direct · 2 efficacy
Linked drugDOXYCYCLINE
Linked drugDOXYCYCLINE HYCLATE
Approved-linked Approved
periodontitis
2 linked drugs · 2 direct · 2 efficacy
Linked drugDOXYCYCLINE
Linked drugDOXYCYCLINE HYCLATE
Approved-linked Approved
rosacea
2 linked drugs · 2 direct · 2 efficacy
Linked drugDOXYCYCLINE
Linked drugDOXYCYCLINE HYCLATE
Approved-linked Approved
anthrax infection
1 linked drug · 1 direct · 1 efficacy
Linked drugDOXYCYCLINE
Approved-linked Approved
bacterial disease
1 linked drug · 1 direct · 1 efficacy
Linked drugDOXYCYCLINE
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with acne because it currently carries approved-linked support. Linked drugs include DOXYCYCLINE, DOXYCYCLINE HYCLATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseacne
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

3
Approved
2
Phase III
5
Phase II
1
Phase I
Assay Mix

Activity Type Distribution

IC501,090.0
KI668.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL2064547 10.7 IC50 0.02 Preclinical
CHEMBL2064548 10.52 IC50 0.03 Preclinical
CHEMBL2064549 10.4 IC50 0.04 Preclinical
CHEMBL11306 10.34 IC50 0.046 Preclinical
CHEMBL2425938 10.3 IC50 0.05 Preclinical
CHEMBL440498 10.01 IC50 0.097 Clinical
CHEMBL306524 10.0 Ki 0.1 Preclinical
CHEMBL293503 10.0 Ki 0.1 Preclinical
CHEMBL2064542 9.96 IC50 0.11 Preclinical
CHEMBL70417 9.96 Ki 0.11 Preclinical
Distribution

pChEMBL Value Distribution

69
5.0
87
5.5
137
6.0
186
6.5
164
7.0
162
7.5
178
8.0
164
8.5
81
9.0
16
9.5
pChEMBL
Assay Landscape

Assay Landscape

230
Total Assays
1,317
Tested Compounds
3
Assay Types
Binding — 220 assays, 1,317 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 200 1,194 7.1
assay format 11 30 5.5
cell-based format 9 93 5.3
ADME — 9 assays, 27 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 7 22 6.8
assay format 2 5 7.1
Unassigned — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine